{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:43:26Z","timestamp":1791186206285,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.diagmicrobio.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:07:54Z","timestamp":1557360474000},"page":"166-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China"],"prefix":"10.1016","volume":"95","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pupt.2014.06.002","article-title":"Current and future therapies for invasive aspergillosis","volume":"32","author":"Bassetti","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-014-9772-2","article-title":"Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values","volume":"178","author":"Castanheira","year":"2014","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2005.12.005","article-title":"Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis","volume":"27","author":"Cernicka","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0025","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1038\/emi.2017.97","article-title":"Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China","volume":"6","author":"Deng","year":"2017","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0030","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fmicb.2017.00464","article-title":"Notable increasing trend in azole non-susceptible Candida tropicalis causing invasive candidiasis in China (August 2009 to July 2014): molecular epidemiology and clinical azole consumption","volume":"8","author":"Fan","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3760\/cma.j.issn.0366-6999.2010.05.007","article-title":"Relationship between antifungal resistance of fluconazole resistant Candida albicans and mutations in ERG11 gene","volume":"123","author":"Feng","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0045","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/jac\/dkt083","article-title":"Invasive candidiasis in intensive care units in China: a multicentre prospective observational study","volume":"68","author":"Guo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0050","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fmicb.2016.01382","article-title":"Epidemiological and genomic landscape of azole resistance mechanisms in Aspergillus fungi","volume":"7","author":"Hagiwara","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0055","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3389\/fmicb.2017.00880","article-title":"Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (August 2009 to July 2014): a multi-center study","volume":"8","author":"Hou","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0060","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/jac\/dks481","article-title":"Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China","volume":"68","author":"Jiang","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0070","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1128\/jcm.35.5.1216-1223.1997","article-title":"Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5\u2032 end of the large-subunit (26S) ribosomal DNA gene","volume":"35","author":"Kurtzman","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.resmic.2015.02.009","article-title":"Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China","volume":"166","author":"Liu","year":"2015","journal-title":"Res Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0080","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1128\/AAC.00003-15","article-title":"Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jac\/dkt330","article-title":"Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study","volume":"69","author":"Liu","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0090","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.47.2.577-581.2003","article-title":"Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase","volume":"47","author":"Mann","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-015-0348-3","article-title":"Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0100","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2015.0460","article-title":"Clinical implications of globally emerging azole resistance in Aspergillus fumigatus","volume":"371","author":"Meis","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/17512433.2015.1034689","article-title":"Pharmacologic and clinical evaluation of posaconazole","volume":"8","author":"Moore","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/myc.12299","article-title":"In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012","volume":"58","author":"Pfaller","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0120","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JCM.00937-12","article-title":"Progress in antifungal susceptibility testing of Candida spp. by use of clinical and laboratory standards institute broth microdilution methods, 2010 to 2012","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0125","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1128\/JCM.00535-08","article-title":"In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/JCM.01952-07","article-title":"Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0135","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1099\/jmm.0.000123","article-title":"Overexpression and mutation as a genetic mechanism of fluconazole resistance in Candida albicans isolated from human immunodeficiency virus patients in Indonesia","volume":"64","author":"Rosana","year":"2015","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0140","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1117018109","article-title":"Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi","volume":"109","author":"Schoch","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0145","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Segal","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0150","first-page":"2706","article-title":"In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin","volume":"123","author":"Shi","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0155","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/AAC.01599-09","article-title":"Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling","volume":"54","author":"Snelders","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0160","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.fgb.2011.08.002","article-title":"The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance","volume":"48","author":"Snelders","year":"2011","journal-title":"Fungal Genet Biol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0165","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11046-014-9831-8","article-title":"The A395T mutation in ERG11 gene confers fluconazole resistance in Candida tropicalis causing candidemia","volume":"179","author":"Tan","year":"2015","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0175","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1567-1364.12042","article-title":"Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans","volume":"13","author":"Xiang","year":"2013","journal-title":"FEMS Yeast Res"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0180","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dku460","article-title":"Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance","volume":"70","author":"Xiao","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0185","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/fmb.14.18","article-title":"Elucidating drug resistance in human fungal pathogens","volume":"9","author":"Xie","year":"2014","journal-title":"Future Microbiol"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0190","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jac\/dkn015","article-title":"Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations","volume":"61","author":"Xu","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0195","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/mdr.2012.0204","article-title":"In vitro fluconazole susceptibility of 1,903 clinical isolates of Candida albicans and the identification of ERG11 mutations","volume":"19","author":"Ying","year":"2013","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.diagmicrobio.2019.05.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02496-16","article-title":"ERG11 gene mutations and MDR1 upregulation confer pan-azole resistance in Candida tropicalis causing disseminated candidiasis in an acute lymphoblastic leukemia patient on posaconazole prophylaxis","volume":"61","author":"You","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318308241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318308241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:52:55Z","timestamp":1760003575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318308241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0732889318308241"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.003","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}